Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Tropical Medicine Drug Data - A-Z (Espanol)
Drug Class Description
AntimalaricosDrug Description
COMPRIMIDOSPresentation
Profilaxis malaria:. -- Adultos y niños mayores de 10 años: 25 mg/semana. -- Niños de 5-10 años: 12,5 mg/semana. Comenzar la profilaxis inmediatamente antes de ir a un área endémica y continuar 1 vez/semana. Mantener la dosis durante 4 semanas al volver a un área no endémica. Tratamiento malaria (junto con sulfaleno o sulfadoxina):. -- Adultos y niños mayores de 14 años: 50-75 mg de pirimetamina + 1-1,5 mg de sulfaleno o sulfadoxina, en dosis única. -- Niños de 9-14 años: 50 mg de pirimetamina + 1 g de sulfaleno o sulfadoxina, en dosis única. -- Niños de 4-8 años: 25 mg de pirimetamina + 0,5 g de sulfaleno o sulfadoxina, en dosis única. Toxoplasmosis (con sulfadiazina u otra sulfonamina adecuada):. -- Adultos y niños mayores de 6 años: inicialmente, 50 mg seguidos de 25 mg/día. Sulfadiazina: 37,5 mg/kg/6 h. -- Niños de 2-6 años: inicialmente, 25 mg seguidos de 12,5 mg/día. Sulfadiazina: 37,5 mg/kg/6 h. El uso de una sulfonamida alternativa puede requerir ajuste de dosis. Duración del tratamiento: 3-6 semanas. Si se inidica terapia adicional, intercalar 2 semanas entre los tratamientos.Indications
- Malaria: tratamiento y profilaxis. - Toxoplasmosis: en combinación con sulfonamida.Child Dosage
No se han registrado problemas específicamente pediátricos en este grupo de edad, no obstante, los niños pueden presentar una mayor susceptibilidad a los efectos adversos derivados de una intoxicación por pirimetamina, por lo que se recomienda especial precaución en mantener el medicamento fuera del alcance de los niños. Uso aceptado en niños (para cada indicación consultar el apartado de posología).Elderly Dosage
No se dispone de suficiente experiencia clínica en este grupo de edad. Uso precautorio, recomendándose un estricto control clínico.Contra Indications
Alergia al medicamento.Special Precautions
Trastornos convulsivos (a dosis elevadas). Se recomienda recuentos sanguíneos periódicos durante tratamientos prolongados. Administrar profilácticamente folinato cálcico cuando se utilicen dosis elevadas (tratamiento de la toxoplasmosis). Deficiencia de glucosa-6-fosfato deshidrogenasa, ya que puede precipitar un cuadro de anemia hemolítica. Malnutrición o desnutrición, ya que es más probable la aparición de anemia megaloblástica. No es recomendable una exposición prolongada al sol ante el riesgo de que puedan producirse manifestaciones de fotosensibilidad.Interactions
- El ácido p-aminobenzoico y el ácido fólico pueden interferir sus efectos antitoxoplásmicos, por antagosnimo farmacodinámico. - Cianocobalamina puede aumentar la gravedad de las alteraciones hematológicas. - Lorazepam: hay estudios en los que se ha registrado potenciación de la toxicidad hepática. - Metotrexato: pirimetamina puede provocar exacerbación de los efectos mielosupresores de los agentes citostáticos, especialmente los de acción antifolato como metotrexato. - Sulfametoxazol-trimetoprim: hay estudios en los que se ha registrado potenciación de la toxicidad, con aparición de anemia megaloblástica y pancitopenia, por adición de sus mecanismos inhibidores de la dihidrofolato reductasa.Adverse Reactions
Administrado en 1 toma semanal carece de efectos tóxicos. Administrado diariamente durante periodos prolongados (toxoplasmosis), puede provocar frecuentemente deficiencia de ácido fólico manifestada por: anemia megaloblástica, depresión de la médula ósea y trastornos gastrointestinales, insomnio y erupciones cutáneas.Manufacturer
WELLCOME FARMACEUTICADrug Availability
APORTACION REDUCIDA (CICERO)Advert for Healthcare Professionals Only
Latest News
13th February 2012
Cyberknife (Accuray Inc) relieves pain of Trigeminal Neuralgia facial nerve condition Page
Cyberknife, the Intensity Modulated RadioTherapy system from Accuray Inc, can relieve the stabbing pain of the facial nerve condition Trigeminal Neuralgia. Researchers treated 17 patients with Trigeminal Neuralgia with Cyberknife radiosurgery between 2007 and 2009. The patients, who were aged between 36 and 90, had had their symptoms for between one and 11 years and had not responded to the available treatment options. The researchers zapped a 6mm length of trigeminal nerve, just 2 to 3mm from the root, using a maximum radiation dose of 73.06 Gy. The patients were then monitored regularly after the procedure, for an average of just under 12 months. Complete data were available for 16 patients, 14 of whom obtained either partial or complete relief from their symptoms. The average time before symptom relief occurred was just under two months, but varied from three weeks to six months. Four patients relapsed after the procedure, between three and 18 months later. No patient experienced major complications as a result of the procedure, and only two patients reported any sensory side effects. See: >"Cyberknife radiosurgery in treating trigeminal neuralgia" by Bryan M Lazzara et al. Journal of NeuroInterventional Surgery (2012). doi:10.1136/neurintsurg-2011-010125
FDA approves trial of Celution System (Cytori Therapeutics) for CMI Cardiology Page
Cytori Therapeutics has received an Investigational Device Exemption (IDE) approval from the FDA to begin the ATHENA trial using its Celution System. ATHENA will investigate the use of the Celution System to treat a form of Coronary Heart Disease, Chronic Myocardial Ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011. The trial will enroll up to 45 patients with no-option CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12-months.
Phase III Trial of MDV 3100 (Medivation/Astellas) in Prostate Cancer patients shows positive results Oncology Page
Researchers have presented positive results on all efficacy endpoints from the Phase III AFFIRM trial of the investigational drug MDV 3100, from Medivation and Astellas, in men with Prostate Cancer previously treated with chemotherapy. The results, presented at the 2012 Genitourinary Cancers Symposium, show that men taking MDV 3100 lived for a median of 18.4 months, compared with 13.6 months for men taking placebo. MDV 3100 also met all secondary endpoints, including radiographic progression-free survival (8.3 versus 2.9 months; PSA declines of 50% or greater were more common in the MDV 3100 group than in the placebo group (54.0% versus 1.5%; and MDV 3100 was found to be well tolerated. The data was presented by Howard I. Scher, chief, Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center.
